ClinicalTrials.gg
CompletedNCT00774345Updated Dec 2, 2021Results posted

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

A Phase 3 interventional study of Lenalidomide and Placebo in B-cell Chronic Lymphocytic Leukemia, sponsored by Celgene. Completed at 241 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-02.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
3rd of 77
317 · median 29
Started
2009
with 9 others
Phase 3
3 of 78
none open now
Registered
19th of 78
by date
Lead sponsor
4 of 78
Celgene

Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 3rd largest by enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2009, is one of 3 in phase 3, and was the 19th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.

Read the detailed description

This is a phase 3, randomized (computer assigned by chance to treatment arm), study being completed an multiple sites to compare the safety and efficacy (how well a drug works) of lenalidomide maintenance therapy to placebo (dummy capsule that contains no lenalidomide or active substances) maintenance therapy.

Patients are assigned by a computer with a 50/50 chance to receive placebo or lenalidomide study treatment. Study drug will be taken once each day until the patient discontinues the study. Patients will remain on study drug until progression of disease.

Patients will visit their study doctor every 28 days until disease progression to complete safety and efficacy assessments. Quality of life assessments will be completed every other month. If a patient who discontinue study drug prior to disease progression (i.e. due to an adverse reaction to the study drug), they will continue to visit the study doctor each month to complete the efficacy assessments up to progression of disease. Safety assessments may include laboratory blood tests, ECG tests and questions about any medical conditions or side effects experienced during the study. Efficacy assessments may include laboratory blood tests and focused physical exams.

Computed tomography (CT) scans along with blood tests and bone marrow samples will be collected to confirm if a patient has improvement of response while on study.

After disease progression, patients will be contacted every 12 weeks for survival information, next CLL treatments and quality of life questions.

Subjects currently on lenalidomide treatment will discontinue lenalidomide treatment immediately and complete the Treatment Discontinuation assessment. The subjects will then transition to the survival follow-up period.

03

Conditions studied

  • B-cell Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must understand and voluntarily sign an form.
  2. Must be greater than or equal to 18 years at the time of signing the informed consent form.
  3. Must be able to adhere to the study visit schedule and other protocol requirements.
  4. Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia [Hallek, 2008]).
  5. Must have been treated with one of the following in first and/or :

    • a purine analog-containing regimen
    • a bendamustine-containing regimen
    • an anti-CD20 antibody-containing regimen
    • a chlorambucil-containing regimen
    • an alemtuzumab-containing regimen (for those subjects with a 17p deletion)
  6. Must have achieved a minimum response of partial response (PR, nPR, CRi, CR, and MRD-negative CR) (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia [Hallek, 2008]) following completion of second-line induction therapy prior to randomization (documentation of response status must be available). Second-line induction therapy must be documented to have been of sufficient duration.
  7. Must have completed last cycle of second-line induction no less than 8 weeks (56 days) and no greater than 20 weeks (140 days) prior to randomization.
  8. Must have an performance status score of less than or equal to 2.
  9. Females of (FCBP)† must:

    • Have two negative medically supervised pregnancy tests prior to starting of study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices complete and continued sexual abstinence.
    • Either commit to continued abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.
  10. Male subjects must:

    • Commit to continued abstinence from heterosexual contact or agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy.
    • Agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
  11. All subjects must:

    • Have an understanding that the study drug could have a potential teratogenic risk.
    • Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy. • Agree not to share study medication with another person.
    • All subjects must be counseled about pregnancy precautions and risks of fetal exposure.

Exclusion criteria

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Active infections requiring systemic antibiotics.
  3. Systemic infection that has not resolved > 2 months prior to initiating lenalidomide treatment in spite of adequate anti-infective therapy
  4. or allogeneic bone marrow transplant as therapy.
  5. Pregnant or lactating females.
  6. Systemic treatment for B-cell CLL in the interval between completing the last cycle of second-line induction therapy and randomization.
  7. Participation in any clinical study or having taken any therapy for a disease other than CLL within 28 days prior to initiating maintenance therapy.
  8. Known presence of alcohol and/or drug abuse.
  9. Central nervous system involvement as documented by spinal fluid cytology or imaging. Subjects who have signs or symptoms suggestive of leukemic meningitis or a history of leukemic meningitis must have a lumbar puncture procedure performed within two weeks prior to randomization.
  10. Prior history of , other than CLL, unless the subject has been free of the disease for ≥5 years. Exceptions include the following:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
  11. History of renal failure requiring dialysis.
  12. Known (HIV), active Virus (HBV), and/or active Virus (HCV) infection.
  13. Prior therapy with lenalidomide.
  14. Evidence of TLS per the Cairo-Bishop definition of laboratory TLS (subjects may be enrolled upon correction of electrolyte abnormalities).
  15. Any of the following laboratory abnormalities:

    • Calculated (method of Cockroft-Gault) \<60 mL/min.
    • (ANC) \<1,000/μL (1.0 X 109/L)
    • count \<50,000/μL (50 X 109/L)
    • Serum (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x (ULN)
    • Serum total >2.0 mg/dL (with the exception of Gilbert's Syndrome)
  16. Grade 4 rash due to prior thalidomide treatment
  17. Uncontrolled hyperthyroidism or hypothyroidism
  18. Venous thromboembolism within one year
  19. Greater than or equal to Grade-2 neuropathy
  20. Uncontrolled hemolytic anemia or thrombocytopenia
  21. Disease transformation (active) (ie, Richter's Syndrome, prolymphocytic leukemia)
  22. Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.
  23. Prisoners.
  24. More than 2 prior lines of CLL therapy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Experimental: 1

    Lenalidomide po qd on days 1-28 of a 28 day cycle

    Drug: Lenalidomide

  • Placebo comparator
    Placebo Comparator: 2

    Placebo capsules given orally on days 1-28 of a 28 day cycle

    Drug: Placebo

Interventions

  • Lenalidomide capsules given orally on days 1-28 of a 28 day cycle

    Also known as: Revlimid

  • DrugPlacebo

    Placebo capsules given orally on days 1 - 28 of a 28 day cycle

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death from any cause. OS will be censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: Up to approximately 11 years

Secondary outcomes

  1. Progression Free Survival 2 (PFS2)

    Progression Free Survival (PFS2) assessed by investigator is defined as the time from randomization to the second objective disease progression, or death from any cause, whichever occurs first.

    Time frame: Up to 6 years

  2. Number of Participants With Adverse Events (AEs)

    Number of participants with adverse events (AEs) that measure type, frequency and severity of AEs graded by National Cancer Institute Common Terminology Criteria (NCI CTCAE V 3.0) including any grade adverse events (AEs), Grade 3-4 AEs, AEs related to study drug, grade 3-4 AEs related to study drug.

    Time frame: From first dose to 30 days post last dose (up to 9 years)

07

Results

Posted Dec 2, 2021

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneLenalidomidePlacebo
Started160157
Completed158157
Not completed20
Withdrew: Other reasons20
Treatment
Participant flow — Treatment
MilestoneLenalidomidePlacebo
Started158157
Participants escalated to 5mg129149
Participants escalated to 10mg6888
Completed00
Not completed158157
Withdrew: Adverse event6115
Withdrew: Progressive disease without histologic transformation51111
Withdrew: Progressive disease with histologic transformation42
Withdrew: Withdrawal by subject52
Withdrew: Lost to follow-up11
Withdrew: Death40
Withdrew: Other reasons3226

Outcome measures

PrimaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from randomization to death from any cause. OS will be censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
Up to approximately 11 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenalidomidePlacebo
Overall Survival (OS)95.09 (70.35 to 103.52)73.28 (59.98 to 102.98)
Statistical analysis
  • Lenalidomide vs Placebo · Log Rank · p = 0.276 (The p-value is based on a stratified log-rank test.) · Hazard ratio (hr): 0.84 · 95% CI 0.61 to 1.15Based on the stratified cox proportional hazards model comparing the hazard functions associated with the treatment groups.
SecondaryProgression Free Survival 2 (PFS2)

Progression Free Survival (PFS2) assessed by investigator is defined as the time from randomization to the second objective disease progression, or death from any cause, whichever occurs first.

Time frame:
Up to 6 years
Reported as:
Median · Months
Progression Free Survival 2 (PFS2)
MonthsLenalidomidePlacebo
Progression Free Survival 2 (PFS2)NA (49.5 to NA)35.9 (27.4 to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

Number of participants with adverse events (AEs) that measure type, frequency and severity of AEs graded by National Cancer Institute Common Terminology Criteria (NCI CTCAE V 3.0) including any grade adverse events (AEs), Grade 3-4 AEs, AEs related to study drug, grade 3-4 AEs related to study drug.

Time frame:
From first dose to 30 days post last dose (up to 9 years)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsLenalidomidePlacebo
Adverse Events (AEs)155149
Grade 3-4 AEs13673
AEs related to Study drugs14398
Grade 3-4 AEs related to Study drugs11741

Adverse events

Collected over Up to 9 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide78/158 (49.4%)99/158 (62.7%)152/158 (96.2%)
Placebo80/157 (51%)49/157 (31.2%)140/157 (89.2%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventLenalidomidePlacebo
NeutropeniaBlood and lymphatic system disorders49/15813/157
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/1588/157
PneumoniaInfections and infestations7/1588/157
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/1584/157
ThrombocytopeniaBlood and lymphatic system disorders7/1580/157
SepsisInfections and infestations5/1580/157
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/1581/157
PyrexiaGeneral disorders3/1583/157
Anaemia haemolytic autoimmuneBlood and lymphatic system disorders3/1582/157
Febrile neutropeniaBlood and lymphatic system disorders3/1580/157
Most frequent other events
Showing 10 of 56
Most frequent other events
EventLenalidomidePlacebo
NeutropeniaBlood and lymphatic system disorders106/15844/157
DiarrhoeaGastrointestinal disorders65/15826/157
FatigueGeneral disorders56/15854/157
CoughRespiratory, thoracic and mediastinal disorders46/15832/157
ThrombocytopeniaBlood and lymphatic system disorders44/15819/157
RashSkin and subcutaneous tissue disorders42/15813/157
Night sweatsSkin and subcutaneous tissue disorders30/15831/157
Upper respiratory tract infectionInfections and infestations31/15828/157
PyrexiaGeneral disorders28/15817/157
NauseaGastrointestinal disorders26/15827/157

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LenalidomidePlaceboTotal
Mean62.9 ± 8.0862.5 ± 8.8562.7 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)LenalidomidePlaceboTotal
Female454489
Male115113228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LenalidomidePlaceboTotal
Hispanic or Latino617
Not Hispanic or Latino153156309
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LenalidomidePlaceboTotal
American Indian or Alaska Native000
Asian325
Native Hawaiian or Other Pacific Islander011
Black or African American145
White154150304
More than one race000
Unknown or Not Reported202
08

Study locations

241 sites
  • Mayo Clinic - Arizona
    Phoenix, Arizona 85054, United States
  • Pacific Coast Hematology Oncology
    Fountain Valley, California 92708, United States
  • Kaiser Permanente Medical Group
    San Diego, California 92120, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • Stanford University Stanford
    Stanford, California 94305, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218-1210, United States
  • Cancer Center of Central Connecticut
    Plainville, Connecticut 06062, United States
  • Boca Raton Community Hospital
    Boca Raton, Florida 33486, United States
  • Pasco Hernando Oncology Associates, PA
    Brooksville, Florida 34613, United States
  • Memorial Hospital
    Hollywood, Florida 33021, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • Florida Cancer Specialist
    Tavares, Florida 32778, United States
  • Florida Hospital Cancer Institute Waterman
    Tavares, Florida 32778, United States
  • Augusta Oncology Associates, P.C.
    Augusta, Georgia 30901, United States
  • Northwest Georgia Oncology Centers, PCWilliam S. Gibbons Center Research Institute
    Marietta, Georgia 30060, United States
  • Northwestern University, Division of Hematology Oncology, Dept. of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426-3558, United States
  • Edward Hines Jr VA Hospital
    Hines, Illinois 60141, United States
  • North Chicago VA Medical Center
    North Chicago, Illinois 60064, United States
  • Hematology Oncology Assoc. of IL Orchard Research LLC
    Skokie, Illinois 60076, United States
  • Floyd Memorial Cancer Center of Indiana, a division of Floyd Memorial Hospital and Health Services
    New Albany, Indiana 47150, United States
  • McFarland Clinic
    Ames, Iowa 50010, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101-1733, United States
  • Ochsner Medical Institutions
    New Orleans, Louisiana 70121, United States
  • Clinical Unit for Research Trials in Skin CURTIS Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • The Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Biomedical Research Alliance of New York, LLC
    New Hyde Park, New York 11042, United States
  • SUNY Upstate Medical University Medicine Oncology
    Syracuse, New York 13215, United States
  • Westchester County Medical Center
    Valhalla, New York 10595, United States
  • Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Hematology Oncology Consultants, Inc.
    Columbus, Ohio 43235, United States
  • Gabrail Cancer Center Research
    Dover, Ohio 44622, United States
  • Trilogy Cancer Care
    Wooster, Ohio 44691, United States
  • Kaiser Permanente Northwest Oncology Hematology
    Portland, Oregon 97227, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • Drexel University, College of Medicine, Clinical Research Group
    Philadelphia, Pennsylvania 19102, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Abington Hematology Oncology Associates Inc
    Willow Grove, Pennsylvania 19090, United States
  • Charleston Hematology Oncology P.A.
    Charleston, South Carolina 29403, United States
  • M. Francisco Gonzalez, MD, PA
    Sumter, South Carolina 29150, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Wenatchee Valley Hospital and Clinics
    Wenatchee, Washington 98801, United States
  • Gundersen Clinic Lutheran Hospital
    La Crosse, Wisconsin 54601, United States
  • Concord Hospital
    Concord, New South Wales 2139, Australia
  • Haematology and Oncology Clinics of Australasia
    South Brisbane, Queensland 4101, Australia
  • IMVS
    Adelaide, South Australia 5000 SA, Australia
  • Flinders Medical Centre
    Bedford Park, 5042, Australia
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Peter MacCallum Cancer Centre
    East Melbourne, 3006, Australia
  • Frankston Hospital
    Farkston, 3199, Australia
  • St. Vincent Hospital
    Fitzroy, 3065, Australia
  • Nepean Hospital
    Kingswood, NSW, 2751, Australia
  • Clinical Trials Unit The St George Hospital
    Kogarah, 2217, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Royal North Shore HospitalDepartment of HematologyLevel 4
    St. Leonards, 2065, Australia
  • The Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • Universitaetsklinik Innsbruck
    Innsbruck, 6020, Austria
  • Hospital Bamherzige Schwestern
    Linz, 4010, Austria
  • Medical University of Vienna Internalmedicine 1, Hematology
    Vienna, 1190, Austria
  • AZ Sint-Jan AV Brugge
    Brugge, 8000, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Cliniques Universitaires St Luc
    Bruxelles, 1200, Belgium
  • UZ Gent Hematology
    Gent, 9000, Belgium
  • Hopital de Jolimont
    Haine-Saint Paul, 7100, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Mont -Godinne
    Yvoir, 5530, Belgium
  • Regional Health Authority B-Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • General Hospital, Eastern Health
    St John's, Newfoundland and Labrador A1B 3V6, Canada
  • CDHA Centre for Clinical Research
    Halifax, Nova Scotia B3H 1V7, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l'Est-de-l'Ile-de-Montreal
    Montreal/Quebec, Quebec, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
  • Hopital du Sacre-Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
  • Hopital De L'Enfant-Jesus
    Quebec, G1J 1Z4, Canada
  • Oncomedica S.A.
    Monteria, Colombia
  • Interni hematoonkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Poliklinika Agel Novy Jicin
    Novy Jicin, 74101, Czechia
  • Faculty Hospital Plzen
    Plzen, 30460, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 00, Czechia
  • General Faculty Hosital1.Internal Clinic
    Prague, 12808, Czechia
  • Rigshospitalet University Hospital
    Copenhagen, 2100, Denmark
  • Odense University Hospital
    Odense, DK-5000, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • Hopital Aviecenne
    Bobigny Cedex, 93009, France
  • Bergonie Institut
    Bordeaux, 33076, France

Showing the first 100 of 241 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foa R. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017 Nov;4(11):e534-e543. doi: 10.1016/S2352-3026(17)30168-0. Epub 2017 Sep 25. PubMed 28958469 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2009 to primary completion in Oct 2020, 141 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 141 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 17, 2008
StartActual
Jan 27, 2009
Primary completionActual
Oct 27, 2020
CompletionActual
Oct 27, 2020
Results first posted
Dec 2, 2021
Last update
Dec 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00774345
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 17, 2008
Start date
Jan 27, 2009
Primary completion
Oct 27, 2020
Completion
Oct 27, 2020
Results posted
Dec 2, 2021
Last update
Dec 2, 2021

Study contacts

Richard Delarue, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion